Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 14INDUSTRY 14NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × siltuximab × Clear all
NCT00311545 2013-02-20

S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer

SWOG Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00433446 2013-02-05

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

SWOG Cancer Research Network

Phase 2 Completed
62 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡